After surging to new highs in late March, today’s recommendation has pulled back quietly but steadily throughout April and my goal is for readers to get on board somewhere near the bottom of the current correction.

Current Market Outlook


There has been a lot of dramatic headlines recently, and we’ve even seen some sharp market moves. But net-net, the market remains where it’s been for the past few weeks—generally stuck in a tight trading range, with some stocks doing well, some faltering and most just biding their time. Long-term, we’re still optimistic that the next major move will be up, based on the still-bullish major trend of the indexes, the lack of selling pressure on the broad market and numerous studies that point toward higher prices in the months ahead. Because of that, we’re all for holding your strong performers, and it’s fine to pick up shares of new leaders at good buy points. But it’s best to quickly get rid of losers and hold a little cash until the buyers flex their muscles.

This week’s list has a nice mix of growth stories and turnaround situations. Our Top Pick is FMC Corp. (FMC), an agricultural chemicals firm that soared last week after a game-changing acquisition that should significantly boost earnings.

Stock Name	Price	Buy Range	Loss Limit
Darden Restaurants (DRI)	106.63	81-83	76-77
FMC Corp. (FMC)	0.00	71-75	65-68
iRobot (IRBT)	103.17	64-66	59-61
Louisiana-Pacific (LPX)	0.00	24.5-26	23-23.5
Madison Square Garden (MSG)	298.38	196-202	186-189
Medidata Solutions (MDSO)	0.00	60.5-63	56-58
Melco Resorts (MLCO)	0.00	18.5-20	17-17.5
Micron Technology, Inc. (MU)	43.31	27-28.5	24.5-25
Qorvo (QRVO)	129.47	69-71.5	65-67
Wright Medical (WMGI)	0.00	29-31	26-27

Today’s stock is in the ultra-glamourous lead-acid battery recycling market. If you want to be a part of what could be the next great industrial revolution, this month’s Cabot Small-Cap Confidential candidate should be right up your alley.

This month’s Cabot Value Model contains a diversified list of Buy recommendations, with a focus on high quality companies with proven records of steady sales, earnings and dividend increases.

While the Cabot Emerging Markets Timer continues to flash a green light, there’s no doubt that buyers and sellers are locked in a battle right now, as the MSCI Emerging Markets ETF has been heading sideways for 15 sessions. In response, we’re doing a bit of house-cleaning in the portfolio.

Contributors remain positive on a variety of industries, beginning with our Spotlight Stock, a giant in the telecom sector that is poised to greatly benefit from cutting-edge tech developments like the mass-market adoption of the Internet of Things and the coming 5G rollout.

Today’s featured stocks include Johnson Controls (JCI), Vertex Pharmaceuticals (VRTX); and a new addition to the Growth & Income Portfolio, TiVo (TIVO).

Today’s recommendation is a case in point. After a long three-year waiting period, the stock broke out to new highs yesterday and followed through today. The stock’s name will probably be familiar to you; its story is certainly interesting.

Current Market Outlook


The market enjoyed a nice bounce after last Monday’s shakeout, especially in growth-oriented sectors and indexes like the Nasdaq. But we don’t think the market is quite out of the woods—by our measures, the intermediate-term trend is still on the fence (most indexes are just above or below their 50-day lines), and the fact is that far fewer stocks are hitting new highs now than the past couple of times the indexes have tested their highs. To be clear, we’re not overly negative, as the longer-term trend looks great, as do many stocks, and the major indexes are just a couple of percent from all-time highs. But we think it’s best to play things carefully (holding some cash, keeping new buys relatively small, etc.) until the market confirms that the post-election uptrend is back on track.

This week’s list is a mixed bag, with some turnarounds, some recent earnings winners and others that have soared on news. For our Top Pick, we’re going with Western Digital (WDC), which, after a brief shakeout, has come storming back to new highs on great volume.

Stock Name	Price	Buy Range	Loss Limit
Huntsman (HUN)	0.00	23-24.5	21-22
Jabil Inc. (JBL)	41.50	27.5-29	26-26.5
Jazz Pharmaceuticals (JAZZ)	0.00	138-144	129-130
Lending Tree (TREE)	411.51	120-124	112.5-115
Penn National Gaming (PENN)	45.38	17.5-18.5	15.8-16.5
PRA Health Sciences Inc. (PRAH)	96.08	63-65	58-59
RH Inc. (RH)	252.93	44-46	40-41.5
Tesla, Inc. (TSLA)	818.87	280-295	260-270
Vertex Pharmaceuticals (VRTX)	230.36	104-109	95-100
Western Digital Corporation (WDC)	0.00	79.5-82.5	73-75

Hello from sunny Florida!

I am on vacation with my family this week, taking a much-needed break from the harsh, snowy Vermont winter (and narrowly making it down here ahead of the latest blizzard to dump another foot or two of snow on the Northeast). But with so much going on in the market – tariffs rejected! GDP growth slowing! AI panic! – I wanted to provide an update on everything that’s going on with our stocks.

It’s the same basic market story as it has been for the last four months. Technology is floundering while other sectors are killing it. But a couple of events occurring this week could potentially change the dynamic.

For value-focused investors, this year’s prologue has been a welcome change from the turmoil experienced in early 2025.

In just the past few weeks, some of last year’s most ignored or underappreciated laggards have posted outsized gains, with rallies that have made even momentum-driven tech stock traders envious. Even more remarkable is the fact that much of that strength has been concentrated in ultra-defensive areas of the market like consumer staples, utilities and healthcare.

The market rotation continues to be the main story out there this week, though rumblings of a potential strike on Iran, an update from the January FOMC meeting, and a slew of earnings reports and economic data releases have been giving investors plenty to think about.

In terms of the rotation, the equal‑weight S&P 500 ETF (RSP) is up 5.5% so far this year, illustrating that leadership is broadening beyond the narrow group of mega‑cap stocks that drove much of last year’s performance.

Year to date, the S&P 600 SmallCap Index is up 8.3% and the S&P 400 Mid‑Cap Index is up 7.9%. Both are comfortably outperforming the S&P 500, which is up just 0.1%, and the Nasdaq, which is down 2.1%.

Happy Chinese New Year! The year of the horse is upon us.

China is expecting an incredible 9.5 billion trips to be made during the 40-day Lunar New Year travel period. Chinese automakers are also on the move as the country’s numerous brands sold nearly 200,000 vehicles in Britain last year, doubling their market share to almost 10%.

As U.S. investors have shifted from risk-on to risk-off mode in recent months, a clear disparity between the “haves” and the “have-nots” has materialized.

Let’s start with the “have-nots.” Financials have fared the worst so far this year (-4.7%), followed by technology (-3.1%), communication services and consumer discretionary (-2.8% each). The downturn in the two tech-related sectors in particular is a stark departure from recent years, when technology led the charge of the current bull market.

Cyclical stocks are soaring and technology is floundering in the transformed market.

The bull market is turned upside down. For most of the first three years, technology, and particularly AI stocks, soared while most other stocks did very little. Now, previously meandering stocks are killing it while technology sinks.

Strong fourth-quarter earnings are confirming what the market was already doing.

Current estimates based on earnings reported so far are for 13.2% overall S&P earnings growth for the quarter. It’s a solid quarter and the fifth straight quarter of double-digit earnings growth. In terms of sector performance, cyclical companies are killing it, and technology is floundering, just like before earnings.

Like many coffee aficionados, I have something of a love/hate relationship with Starbucks (SBUX). My main gripe is that the company’s food and beverage offerings have always been pricey compared to the fare served in most fast-food restaurants and run-of-the-mill coffee houses.

The outperformance of small caps continues.

Through Tuesday’s close, the S&P 600 is up 10% year to date versus just 1.6% for the S&P 500.

All but three small-cap sectors are outperforming their large-cap counterpart. The strongest small-cap sectors are materials (+20%), energy (+23%), industrials (+17%), and tech (+11.4%).

Let’s talk about the power of staying invested.

Sure, when the market turns south – and I’m not even sure last week’s mini-dip qualifies – it makes sense to pare back on your weakest stocks and put a larger portion of your portfolio in cash. But taking your ball and going home – selling out of all of your stocks when times are tough – is not a winning strategy. Here’s why.

NOTE: We’re sending this a day early as I’m soon to embark on a trip with the kiddos over the next week. I will be working a good amount from the road, though, and will have updates if need be. Also, next week’s issue will be published as scheduled.

==

WHAT TO DO NOW: The market remains very mixed, with growth measures still generally pointed sideways to down, while the broad market remains in solid shape. What’s interesting, though, is that we’re seeing more growth stocks kick into gear, along with some huge buying action in a few “cyclical growth” names. Tonight we’re making one move—adding a half-sized stake in Macom Tech (MTSI)—but are keeping our eyes open for a broader character change among growth stocks. Our cash position will be around 53%.

Shares of Chembio (CEMI) have been on the ropes for a few weeks, and over the last two days, they have deteriorated even more. Sell.

Today, we’re going to add a stock we think can be a liquid leader of the new market uptrend: Alibaba (BABA), China’s e-commerce giant.

eMagin (EMAN) and Chembio (CEMI) reported earnings and are rated Hold.

PFSweb (PFSW) reported a better-than-expected quarter with revenue up 22%. Let’s keep it at Hold until we can assess the stock’s reaction

We’re selling Ligand Pharmaceuticals (LGND), which, despite reporting a fine quarter last week, has come under severe selling pressure and broken down decisively. We’ll cut the loss tonight. That move will leave us with three empty slots and a cash position of around 23%. That seems high given the market environment, so we will add one stock—Amazon (AMZN).

Our Cabot Top Ten Trader’s market timing system consists of two parts—one based on the action of three select, growth-oriented market indexes, and the other based on the action of the fast-moving stocks Cabot Top Ten features.